We believe surgeon preference with our open console and modular design, our leading position in minimally invasive surgery and instrumentation, our connected digital ecosystem and data enabled insights, along with our world-class surgical training program and partnerships will meaningfully advance the low penetration of robotic surgery around the world. And in Diabetes, our customer base is expanding sequentially as users around the world purchase the MiniMed 780G system. 780G is the only AID system to make correction boluses every five minutes, offer flexible glucose targets as low as 100, and feature meal detection technology. This combination is resulting in high time and range. Users are achieving or exceeding their glycemic targets, and importantly, realizing the relief that comes from burden reduction in their diabetes management.
In Q2, our diabetes business grew 7%, its highest growth in 10 quarters or five years when you exclude the COVID comp in Q4 of FY ‘21. In international markets, we continue to see robust mid-teens growth driven by the recurring revenue from CGM and consumable sales to customers that have adopted our AID technology. And in the U.S., this was our first full quarter of the 780G launch, and we’re meeting or exceeding our launch goals. Our U.S. pump sales increased over 30% sequentially. The number of unique 780G prescribers has increased over 20% since last quarter, with many returning to Medtronic as they learn about the differentiated outcomes users are getting with 780G. And we also continue to see very high CGM attachment rates in our 780G installed base, meaningfully above the rates prior to launch.
All of these leading indicators give us confidence that we’ll see a significant ramp in our CGM and consumable sales in the U.S. and return to year-over-year growth in the back half of this fiscal year. We’ve been driving this turnaround, and as we look ahead, we expect diabetes to drive even more meaningful growth for us. We expect the majority of the intensive insulin management space to move to smart dosing through either AID systems or smart MDI. And we’re well positioned to take advantage of this trend, as we’re the only company investing in a complete ecosystem of differentiated technology for people living with diabetes, including next generation durable pumps, smart pens, patch pumps, sensors, and algorithms. So with that, let’s go to Karen for a deeper look at our Q2 financial performance and our fiscal ‘24 guidance raise.
Karen?
Karen Parkhill: Thanks, Geoff. Looking at our financials, overall it was another good quarter. Our revenue grew 5% ahead of expectations, and adjusted EPS was $1.25, $0.07 above the midpoint of our guidance range, with about $0.03 from stronger-than-expected revenue $0.03 from better gross margin, and approximately $0.01 coming below the operating profit line. As Geoff mentioned, we remain focused on delivering durable growth. Based on the changes we’ve made, including our operating model, incentives, and capital allocation, we’ve positioned the company to deliver sustainable mid-single-digit growth on the top line. And you are seeing that play out for four quarters in a row now. Looking at our second quarter revenue growth, you can see the diversification coming through, which is important to driving long-term durability.
As Geoff stated, our three portfolios grew mid-single-digits, and diabetes accelerated to high-single-digit growth. The broad-based growth also came through on a geographic basis. Western Europe grew high-single-digits, with strength across many cardiovascular businesses, diabetes, neurovascular, and pelvic health. And Japan grew mid-single-digits and was also driven by strong results in many cardiovascular businesses, as well as surgical and neurovascular. Emerging markets grew 9% or 13%, when excluding Russia given the sanctions. We had low-20s growth in the Middle East and Africa, high-teens growth in South Asia, mid-teens growth in Southeast Asia, and low-double-digit growth in Latin America. China grew high-single-digits, as some of the VBP that we expected was delayed until later in the fiscal year.
While our adjusted gross and operating margins declined in the quarter, both were ahead of expectations. With gross margin, about a third of the year-over-year change was due to currency, and the remainder was driven by inflation. And our adjusted op margin decline was entirely driven by currency. On a constant currency basis, it increased 40 basis points. We’re executing to implement efficiencies in our expense structure, and you can see this in the 90 basis point improvement in SG&A. Below the operating margin line, we benefited from higher global interest rates on our investments, and this was partially offset by a higher-than-expected tax rate, mainly due to jurisdictional mix of profits, as well as a lower benefit from stock-based compensation.